The global Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market is expected to garner a market value of US$ 3 Billion in 2023 and is expected to accumulate a market value of US$ 4.89 Billion by registering a CAGR of 5% in the forecast period 2023 to 2033. The market for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics registered a CAGR of 3.5% in the historical period 2018 to 2022.
The Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market is a segment of the healthcare industry that deals with the effective management of the condition. The market is expected to grow significantly in the coming years due to the increasing prevalence of the condition worldwide. The therapeutics market for FSGS is relatively small, given the rare nature of the disease. There are a few treatment options available that can help manage the symptoms and slow the progression of the disease.
One of the main treatments for FSGS is corticosteroids, such as prednisone, which can help reduce inflammation in the kidneys and decrease proteinuria. Another commonly used treatment is immunosuppressive drugs, such as cyclosporine, which can help control the immune system and reduce kidney damage.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 3 Billion |
| Anticipated Forecast Value (2033) | US$ 4.89 Billion |
| Projected Growth Rate (2023 to 2033) | 5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider, Future Market Insights- the market for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics reflected a value of 3.5% during the historical period, 2018 to 2022. Despite the small market size, the FSGS therapeutics market is expected to grow in the coming years due to increasing awareness of the disease, advances in genetic testing and precision medicine, and the development of new therapies.
Factors such as increasing prevalence of Focal Segmental Glomerulosclerosis (FSGS), increasing prevalence of FSGS, advancements in research and development, government initiatives, growing awareness of FSGS, favorable reimbursement policies for FSGS therapeutics in many countries, and increasing investment in healthcare globally, with pharmaceutical companies investing in the research and development of FSGS therapeutics are expected to drive market growth during this period.
Moreover, strategic collaborations, mergers and acquisitions, and product innovations are expected to further drive the growth of the Focal Segmental Glomerulosclerosis (FSGS) Therapeutics market. Key players in the market are investing in R&D activities to develop new treatment options and improve the efficacy of existing ones. The market offers growth opportunities for pharmaceutical companies, medical device manufacturers, and healthcare providers.
Overall, the market for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics is expected to register a CAGR of 5% in the forecast period 2023 to 2033.
Growing Awareness along with Increasing Prevalence of Focal Segmental Glomerulosclerosis (FSGS) to drive growth
One of the main factors is the increasing prevalence of FSGS worldwide. According to the National Institutes of Health (NIH), FSGS is a rare disease, affecting 7.5 per million people in the United States. However, the incidence of FSGS is increasing, especially in certain ethnic groups, such as African Americans and Hispanics.
In addition to the increasing prevalence of FSGS, advances in research and development are leading to the development of new treatments and therapies for the disease. There are several experimental drugs and therapies being developed for the treatment of FSGS, including monoclonal antibodies, stem cell therapy, and genetic therapies. These new treatments offer hope to patients with FSGS and are expected to contribute to the growth of the market.
Another factor contributing to the growth of the FSGS therapeutics market is increasing awareness and education about the disease. As more information becomes available about FSGS, healthcare providers are better equipped to diagnose and treat the disease. Patients and their families are also becoming more informed about FSGS, which can lead to earlier diagnosis and treatment.
Principal Consultant
Expensive Cost of Treatment to restrict Market Growth
Currently, there are limited treatment options available for Focal Segmental Glomerulosclerosis (FSGS), and none of them are universally effective. Many of the new treatments and therapies for FSGS are expensive, which can limit access to care for some patients. This can be particularly challenging for patients who do not have adequate health insurance coverage or cannot afford the out-of-pocket expenses.
Overall, FSGS is a rare disease, and the patient population is relatively small. This can make it challenging for pharmaceutical companies to invest in developing new treatments and therapies due to the limited potential market.
Increasing awareness and diagnosis of the condition Shaping Landscape for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics in South & East Asia
The Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market in the South & East Asia region is showing significant growth in recent years. This growth is driven by several factors, including the increasing prevalence of FSGS in the region, rising awareness of the disease among patients and healthcare providers, and advances in research and development.
In the South & East Asia region, the prevalence of FSGS is relatively high, especially in countries such as China, India, and Japan. This high prevalence is due to factors such as genetic predisposition, lifestyle changes, and increasing rates of chronic kidney disease in the region.
The increasing awareness of FSGS among patients and healthcare providers is also driving the growth of the market in the South & East Asia region. As more information becomes available about the disease, healthcare providers are better equipped to diagnose and treat the disease, which can lead to improved patient outcomes.
Furthermore, there has been significant progress in research and development of FSGS therapeutics in the South & East Asia region. Several pharmaceutical companies in the region are investing in the development of new drugs and therapies for the treatment of FSGS. For example, Japan-based Kyowa Kirin has developed a monoclonal antibody for the treatment of FSGS, which is expected to be launched in the region soon.
However, there are also challenges in the South & East Asia FSGS therapeutics market. These challenges include limited access to healthcare and expensive treatment options, which can limit patient access to care. Moreover, the lack of awareness of FSGS among the general public and healthcare providers in some countries can also hinder the growth of the market.
Overall, the FSGS therapeutics market in the South & East Asia region is expected to grow significantly in the coming years due to the increasing prevalence of FSGS and the growing awareness of the disease. The region's focus on research and development in FSGS therapeutics also offers opportunities for growth in the market.
Increasing Focus on Technological advancements Shaping Landscape for Focal Segmental Glomerulosclerosis (FSGS) Therapeutics in North America
North America has a relatively high prevalence of FSGS, with the disease being the leading cause of nephrotic syndrome in adults. The high prevalence of FSGS in North America is driving the demand for effective FSGS therapeutics. The region has a well-established research and development infrastructure that is constantly driving innovation in FSGS therapeutics. There have been significant advancements in the understanding of FSGS and its underlying mechanisms, leading to the development of new and effective therapies.
In addition to this, with the increasing awareness of FSGS among healthcare professionals and patients, there is a growing demand for effective FSGS therapeutics in North America. The increasing awareness has led to improved diagnosis and treatment of FSGS, leading to better patient outcomes.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Immunosuppressive agents segment to hold a significant share and push market growth
Based on current trends and ongoing clinical trials, the immunosuppressive agents segment is likely to account for a significant share of the FSGS therapeutics market. Immunosuppressive agents such as calcineurin inhibitors and mycophenolate mofetil have been shown to be effective in managing FSGS in some patients. Additionally, there are several ongoing clinical trials evaluating new immunosuppressive agents for the treatment of FSGS, which is expected to further boost this segment's growth.
Moreover, the monoclonal antibody segment is also expected to gain traction in the FSGS therapeutics market. A monoclonal antibody called rituximab has shown promise in treating some FSGS patients who do not respond to conventional therapy. The development of new monoclonal antibodies for FSGS is also underway, which is expected to drive the growth of this segment.
Key players in the market include companies such as Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc along with healthcare providers and technology companies among other global players.
The NDA submission for sparsentan is based on results from the ongoing Phase 3 PROTECT Study, which is one of the largest interventional studies conducted in IgAN to date. The study evaluated sparsentan in 404 patients with persistent proteinuria and met its pre-specified interim primary efficacy endpoint, which measured changes in proteinuria compared to the active control irbesartan.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 3 Billion |
| Market Value in 2033 | US$ 4.89 Billion |
| Growth Rate | CAGR of 5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled | Competition Deep Dive, Beckman Coulter Inc., Baxter International Inc., ChemoCentryx Inc., Dimerix Ltd, Medtronic PLC, Pfizer Inc., Mylan N.V., Amgen Inc., AstraZeneca plc |
| Customization | Available Upon Request |
The market is valued at US$ 3 Billion in 2023.
Competition Deep Dive, Beckman Coulter Inc., and Baxter International Inc., are key market players.
Immunosuppressive agents are likely to remain preferred through 2033.
The United States market is estimated to dominate the industry with a CAGR of 4.9% during the forecast period.
The market is forecasted to register a CAGR of 5% through 2033.
1. Executive Summary | Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Disease Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Type, 2023 to 2033
5.3.1. Primary FSGS
5.3.2. Secondary FSGS
5.4. Y-o-Y Growth Trend Analysis By Disease Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Disease Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
6.3.1. Corticosteroids
6.3.2. Immunosuppressive Drugs
6.3.3. Plasmapheresis
6.3.4. ACE Inhibitors and ARBs
6.3.5. Diuretics
6.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By Treatment , 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment , 2023 to 2033
7.3.1. Drug Therapy
7.3.2. Dialysis
7.3.3. Kidney Transplant
7.4. Y-o-Y Growth Trend Analysis By Treatment , 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Treatment , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. South Asia
8.3.5. East Asia
8.3.6. Oceania
8.3.7. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. U.S.
9.2.1.2. Canada
9.2.2. By Disease Type
9.2.3. By Drug Class
9.2.4. By Treatment
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Disease Type
9.3.3. By Drug Class
9.3.4. By Treatment
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Disease Type
10.2.3. By Drug Class
10.2.4. By Treatment
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Disease Type
10.3.3. By Drug Class
10.3.4. By Treatment
10.4. Key Takeaways
11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. U.K.
11.2.1.2. Spain
11.2.1.3. Germany
11.2.1.4. Italy
11.2.1.5. France
11.2.1.6. Rest of Europe
11.2.2. By Disease Type
11.2.3. By Drug Class
11.2.4. By Treatment
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Disease Type
11.3.3. By Drug Class
11.3.4. By Treatment
11.4. Key Takeaways
12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Malaysia
12.2.1.3. Indonesia
12.2.1.4. Thailand
12.2.1.5. Rest of South Asia
12.2.2. By Disease Type
12.2.3. By Drug Class
12.2.4. By Treatment
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Disease Type
12.3.3. By Drug Class
12.3.4. By Treatment
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Disease Type
13.2.3. By Drug Class
13.2.4. By Treatment
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Disease Type
13.3.3. By Drug Class
13.3.4. By Treatment
13.4. Key Takeaways
14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. Australia
14.2.1.2. New Zealand
14.2.2. By Disease Type
14.2.3. By Drug Class
14.2.4. By Treatment
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Disease Type
14.3.3. By Drug Class
14.3.4. By Treatment
14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. South Africa
15.2.1.2. GCC Countries
15.2.1.3. Rest of Middle East and Africa
15.2.2. By Disease Type
15.2.3. By Drug Class
15.2.4. By Treatment
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Disease Type
15.3.3. By Drug Class
15.3.4. By Treatment
15.4. Key Takeaways
16. Key Countries Market Analysis
16.1. U.S.
16.1.1. Pricing Analysis
16.1.2. Market Share Analysis, 2022
16.1.2.1. By Disease Type
16.1.2.2. By Drug Class
16.1.2.3. By Treatment
16.2. Canada
16.2.1. Pricing Analysis
16.2.2. Market Share Analysis, 2022
16.2.2.1. By Disease Type
16.2.2.2. By Drug Class
16.2.2.3. By Treatment
16.3. Brazil
16.3.1. Pricing Analysis
16.3.2. Market Share Analysis, 2022
16.3.2.1. By Disease Type
16.3.2.2. By Drug Class
16.3.2.3. By Treatment
16.4. Mexico
16.4.1. Pricing Analysis
16.4.2. Market Share Analysis, 2022
16.4.2.1. By Disease Type
16.4.2.2. By Drug Class
16.4.2.3. By Treatment
16.5. U.K.
16.5.1. Pricing Analysis
16.5.2. Market Share Analysis, 2022
16.5.2.1. By Disease Type
16.5.2.2. By Drug Class
16.5.2.3. By Treatment
16.6. Spain
16.6.1. Pricing Analysis
16.6.2. Market Share Analysis, 2022
16.6.2.1. By Disease Type
16.6.2.2. By Drug Class
16.6.2.3. By Treatment
16.7. Germany
16.7.1. Pricing Analysis
16.7.2. Market Share Analysis, 2022
16.7.2.1. By Disease Type
16.7.2.2. By Drug Class
16.7.2.3. By Treatment
16.8. Italy
16.8.1. Pricing Analysis
16.8.2. Market Share Analysis, 2022
16.8.2.1. By Disease Type
16.8.2.2. By Drug Class
16.8.2.3. By Treatment
16.9. France
16.9.1. Pricing Analysis
16.9.2. Market Share Analysis, 2022
16.9.2.1. By Disease Type
16.9.2.2. By Drug Class
16.9.2.3. By Treatment
16.10. India
16.10.1. Pricing Analysis
16.10.2. Market Share Analysis, 2022
16.10.2.1. By Disease Type
16.10.2.2. By Drug Class
16.10.2.3. By Treatment
16.11. Malaysia
16.11.1. Pricing Analysis
16.11.2. Market Share Analysis, 2022
16.11.2.1. By Disease Type
16.11.2.2. By Drug Class
16.11.2.3. By Treatment
16.12. Indonesia
16.12.1. Pricing Analysis
16.12.2. Market Share Analysis, 2022
16.12.2.1. By Disease Type
16.12.2.2. By Drug Class
16.12.2.3. By Treatment
16.13. Thailand
16.13.1. Pricing Analysis
16.13.2. Market Share Analysis, 2022
16.13.2.1. By Disease Type
16.13.2.2. By Drug Class
16.13.2.3. By Treatment
16.14. China
16.14.1. Pricing Analysis
16.14.2. Market Share Analysis, 2022
16.14.2.1. By Disease Type
16.14.2.2. By Drug Class
16.14.2.3. By Treatment
16.15. Japan
16.15.1. Pricing Analysis
16.15.2. Market Share Analysis, 2022
16.15.2.1. By Disease Type
16.15.2.2. By Drug Class
16.15.2.3. By Treatment
16.16. South Korea
16.16.1. Pricing Analysis
16.16.2. Market Share Analysis, 2022
16.16.2.1. By Disease Type
16.16.2.2. By Drug Class
16.16.2.3. By Treatment
16.17. Australia
16.17.1. Pricing Analysis
16.17.2. Market Share Analysis, 2022
16.17.2.1. By Disease Type
16.17.2.2. By Drug Class
16.17.2.3. By Treatment
16.18. New Zealand
16.18.1. Pricing Analysis
16.18.2. Market Share Analysis, 2022
16.18.2.1. By Disease Type
16.18.2.2. By Drug Class
16.18.2.3. By Treatment
16.19. South Africa
16.19.1. Pricing Analysis
16.19.2. Market Share Analysis, 2022
16.19.2.1. By Disease Type
16.19.2.2. By Drug Class
16.19.2.3. By Treatment
16.20. GCC Countries
16.20.1. Pricing Analysis
16.20.2. Market Share Analysis, 2022
16.20.2.1. By Disease Type
16.20.2.2. By Drug Class
16.20.2.3. By Treatment
17. Market Structure Analysis
17.1. Competition Dashboard
17.2. Competition Benchmarking
17.3. Market Share Analysis of Top Players
17.3.1. By Regional
17.3.2. By Disease Type
17.3.3. By Drug Class
17.3.4. By Treatment
18. Competition Analysis
18.1. Competition Deep Dive
18.1.1. B. Braun Melsungen AG
18.1.1.1. Overview
18.1.1.2. Product Portfolio
18.1.1.3. Profitability by Market Segments
18.1.1.4. Sales Footprint
18.1.1.5. Strategy Overview
18.1.1.5.1. Marketing Strategy
18.1.2. Beckman Coulter Inc.
18.1.2.1. Overview
18.1.2.2. Product Portfolio
18.1.2.3. Profitability by Market Segments
18.1.2.4. Sales Footprint
18.1.2.5. Strategy Overview
18.1.2.5.1. Marketing Strategy
18.1.3. Baxter International Inc.
18.1.3.1. Overview
18.1.3.2. Product Portfolio
18.1.3.3. Profitability by Market Segments
18.1.3.4. Sales Footprint
18.1.3.5. Strategy Overview
18.1.3.5.1. Marketing Strategy
18.1.4. ChemoCentryx Inc.
18.1.4.1. Overview
18.1.4.2. Product Portfolio
18.1.4.3. Profitability by Market Segments
18.1.4.4. Sales Footprint
18.1.4.5. Strategy Overview
18.1.4.5.1. Marketing Strategy
18.1.5. Dimerix Ltd
18.1.5.1. Overview
18.1.5.2. Product Portfolio
18.1.5.3. Profitability by Market Segments
18.1.5.4. Sales Footprint
18.1.5.5. Strategy Overview
18.1.5.5.1. Marketing Strategy
18.1.6. Medtronic PLC
18.1.6.1. Overview
18.1.6.2. Product Portfolio
18.1.6.3. Profitability by Market Segments
18.1.6.4. Sales Footprint
18.1.6.5. Strategy Overview
18.1.6.5.1. Marketing Strategy
18.1.7. Pfizer Inc.
18.1.7.1. Overview
18.1.7.2. Product Portfolio
18.1.7.3. Profitability by Market Segments
18.1.7.4. Sales Footprint
18.1.7.5. Strategy Overview
18.1.7.5.1. Marketing Strategy
18.1.8. Mylan N.V.
18.1.8.1. Overview
18.1.8.2. Product Portfolio
18.1.8.3. Profitability by Market Segments
18.1.8.4. Sales Footprint
18.1.8.5. Strategy Overview
18.1.8.5.1. Marketing Strategy
18.1.9. Amgen Inc.
18.1.9.1. Overview
18.1.9.2. Product Portfolio
18.1.9.3. Profitability by Market Segments
18.1.9.4. Sales Footprint
18.1.9.5. Strategy Overview
18.1.9.5.1. Marketing Strategy
18.1.10. AstraZeneca plc
18.1.10.1. Overview
18.1.10.2. Product Portfolio
18.1.10.3. Profitability by Market Segments
18.1.10.4. Sales Footprint
18.1.10.5. Strategy Overview
18.1.10.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology
Explore Healthcare Insights
View Reports
Focal Segmental Glomerulosclerosis (FSGS) Therapeutics Market
